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A b s t r A c t
bAcKGrOUND: Deceleration capacity (DC) of the heart rate has proved an independ-
ent predictor of total mortality in post-myocardial infarction (post-MI) patients but it 
is unknown whether DC predicts the arrhythmic risk as well.
ObJEctIVE: Our aim was to investigate whether DC can predict the arrhythmic sud-
den cardiac death (SCD) surrogate in patients with heart failure (HF).
PAtIENts AND MEtHODs: We prospectively screened 145 HF patients with electro-
cardiogram (ECG), signal averaged ECG, echocardiography, and 24-hour Holter 
ECG. After 41.2 months, patients were divided into high (n=43) and low risk (n=102) 
groups according to three arrhythmic surrogates: clinical ventricular tachyarrhythmia 
(ventricular tachycardia -VT/ ventricular fibrillation-VF) (n=18), appropriate activa-
tion of the implantable cardioverter defibrillator (ICD) device (n=23) and confirmed 
SCD (n=2).
rEsULts: High risk patients had impaired DC with significantly lower values (3.2±1.8 
ms vs 4.0±2.1 ms, p=0.025). In the Cox regression analysis model adjusted for age, 
gender, diabetes, left ventricular ejection fraction (LVEF), filtered QRS, QTc, non-
sustained VT episode(s) ≥1/24 h, ventricular premature beats ≥240/24 and DC, DC 
emerged as an important SCD surrogate predictor with a hazard ratio of 0.804, (95% 
confidence intervals-CI: 0.671- 0.963, p = 0.018). The cutoff point of DC ≤3.352 ms 
(median) presented a hazard ratio of 2.885 (95% CI: 1.342 - 6.199, p=0.007, log rank 
test: p=0.003) for SCD surrogate.
cONcLUsION: Decreased DC was found to be an important and independent SCD 
surrogate predictor. The cutoff point of DC ≤3.352 ms detects HF patients at in-
creased arrhythmic risk.
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I N t r O D U c t I O N
Heart failure (HF) patients face an increased risk for ar-
rhythmic sudden cardiac death (SCD).1 Malignant ventricular 
arrhythmias constituted a serious lethal threat in the period 
before 1980, when the implantable cardioverter defibrillator 
(ICD) was introduced as the definite prophylactic therapy 
by Dr Mirowski.2 After the establishment of the ICD as an 
efficient therapeutic technique for the protection of patients 
against fatal ventricular arrhythmias,3 a new clinical challenge 
emerged, i.e. although the final prophylactic therapy was 
known, the patient being a candidate for this lethal arrhythmic 
risk was not well defined. In order to solve this problem, differ-
ent risk stratification strategies were introduced and applied.4
Nowadays, the left ventricular ejection fraction (LVEF) 
is used as the prevailing conventional arrhythmia risk strati-
fier even though it is associated with low sensitivity. Current 
research is focused on the development of new risk stratifica-
tion methods. Among the predictors for adverse outcomes 
in post-myocardial infarction (MI) patients, the deceleration 
capacity (DC) of the heart rate has been recently proposed.5 
Previous studies demonstrated DC’s impairment in post-MI 
patients at an increased risk for death,6 in schizophrenics on 
antipsychotic drugs,7 in post-MI patients prior to nonsustained 
ventricular tachycardia (VT) episodes,8 while in combination 
with an impaired heart rate turbulence (HRT), reflecting 
severe autonomic failure, it was associated with an adverse 
outcome in post-MI patients even with a preserved LVEF.9
As it is not clear whether DC, apart from total mortality, 
has any prognostic ability for predicting the arrhythmic SCD 
of HF patients’ risk as well, we designed the present study in 
an attempt to provide some answers.
M E t H O D s  
P A t I E N t s  A N D  s t U D y  D E s I G N
This prospective observational study was approved by 
our Institution’s Ethics Committee and all participants pro-
vided their informed consent. Subjects were hospitalized in 
our department and were referred to our electrophysiology 
laboratory for evaluation for primary or secondary prevention 
of arrhythmic SCD. The study patients had an impaired left 
ventricular systolic function with a LVEF ≤50% due to coro-
nary artery disease (CAD) or dilated cardiomyopathy (DCM). 
Exclusion criteria included ongoing myocardial ischemia 
anticipated to be improved with revascularization, malignant 
diseases affecting survival such as cancer or leukemia, hepatic 
cirrhosis, chronic kidney failure on hemodialysis, stroke-medi-
ated hemiplegia, paraplegia, tetraplegia, psychiatric disease, 
addiction to alcohol/ opioid/ psychiatric medications, dementia 
and diseases affecting the autonomic nervous system (ANS) 
causing dysautonomia. Patients with chronic atrial fibrillation 
were excluded from the study, while those with a history of 
paroxysmal atrial fibrillation were included provided they were 
in sinus rhythm during the recruitment phase.
After obtaining a detailed patient personal and fam-
ily history with medications recording, patients underwent 
physical examination, chest x-ray, blood and biochemical tests, 
12-lead-ECG, echocardiography (Echo), signal averaged ECG 
(SAECG) and 24-hour ambulatory ECG. Subjects with either 
nonsustained ventricular tachycardia (NSVT) episodes and/or 
late potentials were further risk-stratified by electrophysiology 
study (EPS). Patients with inducible ventricular tachycardia/
ventricular fibrillation (VT/VF) on EPS (n=32) as well as 
those with clinical VT/VF (n=13/2 overlap) were candidates 
for an ICD (n=43). From the total sample (n=162), we 
excluded patients with negative DC values (n=17). We pre-
viously proposed10 that the original DC calculation method5 
may produce negative DC values representing acceleration 
and not deceleration, a condition contradicting the principle 
of inter-beat deceleration. In brief, the original DC method 
uses the following steps5: First, all RR intervals longer than 
the previous RR intervals are characterized as DC anchors. In 
this way, the method focuses on the inter-beat decelerations. 
In the next step, segments of the same size of RR intervals 
around the anchors are selected and consequently aligned to 
the anchors. The final phase rectified averaged signal is ob-
tained by averaging the signals within the aligned segments. 
The quantification of DC is based on the following formula: 
DC =[X(0)+X(1)–X(–1)–X(–2)]/4, where X(0) is the aver-
age of the RR intervals at all anchors, X(1) and X(–1) are the 
averages of the RR intervals immediately before and after the 
anchors and X(-2) is the average of the RR intervals before 
X(-1).
When we applied the original method on our data,11 a 
paradox was observed; some patients produced negative DC 
values. From the physiology point of view, when the next 
RR interval decelerates, this cardiac cycle’s interval is longer 
compared to the previous cardiac cycle’s duration. In this 
way, their difference is always positive. A method quantifying 
and extracting the signal’s deceleration capacity is expected 
to always produce positive values. By examining the original 
formula, as the algebraic sum is calculated on four averaged 
intervals, it is possible to extract a negative final algebraic sum 
in cases where X(-2) and (X-1) intervals are longer compared 
to X(0) and X(1) intervals. The physiological meaning of a 
negative value describing inter-beat durations is acceleration 
and not deceleration. For a deeper understanding, let us con-
sider a model of two (averaged) RR intervals. If the second 
(averaged) cardiac cycle is longer than the previous one (real 
deceleration) then only positive DC values must be produced 
from the difference between these two cardiac cycles. The 
original method calculates the DC values from a formula 
using four instead of two (averaged intervals). Because of 
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the selection of a quad final window for the DC calculation, 
it is possible in some patients a negative algebraic sum to be 
extracted. The results of the present study were based on an 
old analysis made via the original DC method. We decided 
to exclude those patients with negative DC values given the 
computed DC value was not reflecting the real deceleration 
of heart rate.
The mean LVEF of the included patients was depressed 
(LVEF = 32.3±10.1%). The follow-up period was 41.2 
months. The primary end-point was based on three SCD-
surrogate events: 1. Clinical VT/VF (n=18), 2. SCD (n=2), 
3. ICD appropriate activation (n=23). The secondary end 
point was total mortality (n= 38). Follow up was completed 
with annual reexamination in the outpatient clinic and with 
telephonic contact. Study’s end-points were double checked 
with the ICD’s interrogation reports provided from the physi-
cians implanting the devices.
E c G  A N D  s I G N A L  AV E r A G E D  E c G  ( s A E c G )
Each participant while in sinus rhythm underwent a rest-
ing supine ECG at 25 mm/sec and a SAECG (MAC 5000 GE 
Medical, Milwaukee, USA) in the same position by the use 
of the three X, y, Z orthogonal bipolar leads (filter: 40-250 
Hz). Conventional criteria for the presence of late potentials 
were used (fQRS: ≥114 ms, LAS: ≥38 ms, RMS: ≤20 μV) for 
those with normal QRS,12 but for patients with intraventricular 
conduction delay with QRS duration ≥120 ms, the modified 
criteria were applied (fQRS: ≥145 ms, LAS: ≥50 ms, RMS: 
≤17.5 μV).13
E c H O c A r D I O G r A P H y
A complete echocardiographic examination was performed 
(SONOS 5500, Hewlett Packard, Andover, Massachusetts, 
USA). LVEF was calculated according to the recommenda-
tions of the American Society of Echocardiography.14
2 4 - H O U r  H O L t E r  M O N I t O r I N G  ( H M )
During the hospitalization period, every patient in sinus 
rhythm underwent 24-hour Holter monitoring (HM) (Spider 
View-1000Hz). The recordings were analyzed using SyneScope 
3.10 software (Spider View & Synescope 3.10, Sorin Group, 
Clamart, France). The events were reviewed and manually 
corrected by a dedicated researcher. The following were cal-
culated: heart rate, RR intervals, ventricular premature beats 
(VPBs), and NSVT episodes. For heart rate variability indices 
(HRV), the included patients had at least 18 hours of good 
quality signal recordings, including less than 12% of filtered 
extra systoles. HRV analysis guidelines were fully observed.15
Heart rate Variability time Domain Analysis: The 
standard deviation (SD) of the normal to normal RR inter-
vals (SDNN) was automatically calculated by Synescope 3.10 
software.
rate corrected Qt Interval: For Holter derived QTc 
interval, a mean complex waveform was calculated based 
on 30 seconds of ECG by the SyneScope 3.10 software. The 
mean 24-hour value of QTc calculated values was extracted 
as a QTc index. Fredericia’s formula was applied for the rate 
correction.16
Deceleration capacity (Dc): For the computation of 
DC and AC the mathematical method based on the original 
algorithm provided for research purposes from the Working 
Group of Biological Signal Analyses in Technische Universität 
München17 was applied on extracted RR time series from the 
patient’s 24 hour Holter recordings.
E L E c t r O P H y s I O L O G y  s t U D y  ( E P s )
A complete electrophysiology study (EPS)18 was performed 
on informed consented patients with either NSVT episodes 
or late potentials (n=58). Ventricular tachycardia inducibil-
ity during EPS was defined as induction of either sustained 
monomorphic VT and/or polymorphic VT degenerating into 
VF (n=32).
s t A t I s t I c A L  A N A Ly s I s
Continuous variables are presented as mean values ± SD 
(standard deviation), while qualitative variables are shown as 
relative frequencies. Differences in clinical characteristics be-
tween the two groups were investigated with t- and Chi-square 
tests. For the purpose of univariate analysis, t-test and log rank 
were applied to examine the associations between non-invasive 
markers and SCD surrogate end points. Multivariate analysis 
was performed using Cox regression models adjusted for age, 
gender, diabetes, LVEF, fQRS, QTc (Fredericia), NSVT 
>1/24h, VPBs>240/24h and DC (continuous/dichotomous 
values). A backward elimination process was applied on all 
multivariate models (using p <5% as the threshold for remov-
ing a variable from the models). All reported p-values are 
based on two-sided tests and compared to a significance level 
of 5%. The results obtained are presented as hazards ratios 
(HR) and the 95% confidence intervals (C.I.). The STATA 8.0 
software (Stata Corporation 2003, Texas, USA) was used in 
all statistical calculations. A value of p <0.05 was considered 
statistically significant.
r E s U L t s
c L I N I c A L  c H A r A c t E r I s t I c s
Patients’ mean age was 64.5±12.3 years; 83% were males. 
Mean LVEF was 32.3±10.1%. Coronary artery disease (CAD) 
was present in 82% of the patients and dilated cardiomyopathy 
(DCM) in 18%. Mean follow-up period was 41.2 months. No 
differences between SCD+ and SCD- surrogate patients were 
observed in age, gender, CAD, ST-elevation MI (STEMI), cor-
onary artery bypass grafting (CABG), percutaneous coronary 
intervention (PCI), DCM, diabetes mellitus, hematocrit, renal 
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function, sodium, potassium and medications. In contrast, the 
SCD+ surrogate group was different in comparison to the 
SCD- surrogate group in LVEF (28.0±9.2% vs 34.1±9.9%, 
p<0.001) and New york Hear Association (NyHA) class 
(2.5±0.5 vs. 2.2±0.5, p=0.002). EPS was performed on 58 pa-
tients with 32 patients demonstrating inducible VT/VF (55%). 
Baseline clinical characteristics are presented in Table 1.
U N I VA r I A t E  A N A Ly s I s
When our data were analyzed for the SCD surrogate pri-
mary end point, the univariate analysis revealed a significant 
difference between the SCD+ and SCD- surrogate groups 
for LVEF (28.0±9.2% vs 34.1±9.9%, p<0.001), for LV end-
diastolic diameter (LVEDD) (60.2±8.1 mm vs 56.3±8.9 mm, 
p=0.026) and for fQRS from SAECG late potentials analysis 
(144±29 ms vs 133±28 ms, p=0.054) while the VPBs cutoff 
point ≥240 episodes/24h (55% vs 37%, p=0.039) and SDNN 
(80±29ms vs 96±36 ms, p=0.009) were also found statisti-
cally different for the two groups. DC was found essentially 
decreased in SCD+ surrogate patients (3.2±1.8 ms vs 4.0±2.1 
ms, p=0.025), whereas AC was not found statistically different 
between the two groups. The results of the univariate analysis 
for arrhythmic end points are presented in Table 2. It is known 
that DC predicts all-cause mortality. Our results for the total 
mortality end point are in accordance with the results of previ-
ous studies confirming them.5 In the univariate analysis, DC 
was substantially lower in the deceased group (2.8±1.6 ms vs 
4.1±2.1 ms, p<0.001), while the LVEF was also found signifi-
tAbLE 1. Baseline Patient Characteristics
characteristics total (n=145) scD + (n=43) scD - (n=102) p value
Age (years) 64.5±12.3 66.2±11.8 65.1±12.5 0.627
Male sex (%) 83 84 81 0.114
CAD (%) 82 86 80 0.418
STEMI (%) 55 53 56 0.772
Non STEMI (%) 10 19 6 0.018
CABG (%) 33 35 32 0.668
PCI (%) 27 16 32 0.090
DCM (%) 18 14 20 0.537 
Diabetes (%) 33 36 32 0.617
LVEF (%) 32.3±10.1 28.0±9.2 34.1±9.9 <0.001
ΝΥΗΑ class 2.2±0.5 2.5±0.5 2.2±0.5 0.002
Ht (%) 41±5 40±5 41 ±5 0.251
Urea (mg/dl) 53±30 59±38 50±26 0.175
Creatinine (mg/dl) 1.3±0.5 1.3±0.4 1.3±0.6 0.995
Sodium (meq/L) 138±3.4 138±3.4 138±3.5 0.922
Potassium (meq/L) 4.3±0.5 4.2±0.5 4.3±0.5 0.401
Medications
Beta-blockers (%) 64 57 67 0.262
Diuretics (%) 58 62 56 0.527
Amiodarone (%) 19 25 17 0.296
CCBs (%) 12 17 10 0.298
CABG = coronary artery bypass grafting; CAD = coronary artery disease; CCBs = calcium channel blockers; DCM = dilated cardiomyopathy; Ht 
= hematocrit; LVEF = left ventricular ejection fraction; NyHA = New york Heart Association (class); PCI = (primary) percutaneous coronary 
intervention; Non STEMI = non-ST elevation myocardial infarction; SCD = sudden cardiac death (surrogate); STEMI = ST-elevation myocardial 
infarction
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cantly reduced in the patients who had deceased (29.2±9.8% 
vs 33.4±10.0%, p=0.025).
M U L t I VA r I A b L E  A N A Ly s I s
Multivariate analysis for the arrhythmic SCD surrogate end 
point was performed with Cox regression analysis. The basic 
model was adjusted for gender, age, diabetes, LVEF, fQRS, 
NSVT ≥1episode/24h, VPBs ≥240beats/24h, QTc (Fredericia), 
and one variable from the 2 indices assessing the ANS activity 
(DC continuous, dichotomous cutoff of DC ≤3.352 ms) was 
added to it each time. Important and independent predictors 
for arrhythmic SCD surrogates proved to be the LVEF with a 
hazard ratio of 0.944 (95% C.I.: 0.908-0.981, p=0.004), the DC 
continuous with a hazard ratio of 0.804 (95% C.I.:0.671-0.963, 
p=0.018), while the dichotomous cutoff point of DC ≤3.352 
ms (median) presented a hazard ratio of 2.885 (95% CI: 1.342 
– 6.199, p=0.007) for arrhythmic SCD surrogates (Log rank 
test, p=0.003). The Kaplan Meier curves for the arrhythmic 
end point (SCD surrogate) are presented in Figure 1. Results 
of the multivariate analysis for SCD end point are presented 
in Table 3. Multivariate analysis for the total mortality was 
tAbLE 2. Arrhythmia Predictors (Mean Values) for SCD+ Surrogate and SCD- Surrogate Groups
Predictors All (n=145) scD+ (n=43) scD - (n=102) p value
ECHO
LVEF (%) 32.3±10.1 28.0±9.2 34.1±9.9 <0.001
LVEDD (mm) 57.4±8.8 60.2±8.1 56.3±8.9 0.026
SAECG
fQRS (ms) 136±29 144±29 133±28 0.054
LAS (ms) 47±29 54±30 44±28 0.065
RMS (μV) 26±17 22±17 28±17 0.082
Noise level(μV) 0.34±0.14 0.37±0.21 0.33±0.10 0.114
HOLTER
NSVT>1/24h (%) 27 37 23 0.099
VPBs>240/24h (%) 42 55 37 0.039
HR24h(bpm) 70±10 71±11 69±9 0.207
SDNN 24h(ms) 91±35 80±29 96±36 0.009
QTc (ms)Fredericia 435±32 440±38 432±29 0.181
DC 3.8±2.1 3.2±1.8 4.0±2.1 0.025
AC -5.8±2.5 -5.4±2.7 -6.0±2.4 0.255
AC = acceleration capacity (of heart rate); DC = deceleration capacity (of heart rate); ECHO = echocardiography; HR = heart rate; fQRS 
= filtered QRS; LAS = low amplitude signal, LVEDD = left ventricular end diastolic diameter; LVEF = left ventricular ejection fraction; 
NSVT = non sustained ventricular tachycardia; QTc = (rate) corrected QT interval; RMS = root mean square; SAECG = signal averaged 
electrocardiogram; SDNN = standard deviation normal to normal beat from heart rate variability analysis; SCD = sudden cardiac death; VPBs = 
ventricular premature beats.
FIGUrE 1. Kaplan Meier curves for arrhythmic end points. The 
subgroup of patients with decreased deceleration capacity (DC), 
under the dichotomous value of DC ≤3.352 ms, present high fre-
quency of arrhythmic events, while the patients with preserved 
deceleration capacity, above the DC >3.352 ms cut off point, 
present lower rates of arrhythmic events. This difference is sig-
nificant: Log rank test = 0.003. SCD = sudden cardiac death.
DC >3.352m
DC >3.352ms
Log rank p=0.003
DC ≤3.352ms
DC ≤3.352m
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tAbLE 3. Multivariate Cox Regression Analysis of the 
Predictors for the Occurrence of SCD Surrogate
Variables Hazard  
ratio 
(95% cI) p value
Male 0.397 0.154-1.027 0.057 
Age 0.975 0.947-1.003 0.088
LVEF 0.944 0.908-0.981 0.004
fQRS - - NS
NSVT>1/24h - - NS
VPBs>240/24h - - NS
QTc - - NS
DC 0.804 0.671-0.963 0.018
AC 1.154 0.999-1.335 0.052
DC Cut off 3.352 ms 2.885 1.342-6.199 0.007
Basic model adjusted for: Gender, Age, Diabetes, LVEF, fQRS, NSVT 
>1/24h, VPBs >240/24h, QTc and one of the variables of DC (DC 
continuous /DC cut off point 3.352 ms) applied on the basic model each 
time. Log rank for DC ≤3.352 ms, p = 0.003.
AC = acceleration capacity of heart rate; CI = confidence intervals; 
DC = deceleration capacity of heart rate; LVEF = left ventricular 
ejection fraction; fQRS = filtered QRS from signal averaged ECG; 
NS = not (statistically) significant; NSVT = non sustained ventricular 
tachycardia (episodes); QTc = rate corrected (according with the 
Fredericia formula) QT interval derived from Holter recordings; SCD 
= sudden cardiac death; VPBs = ventricular premature beats
values. After exclusion of these negative DC values, we found 
that a DC dichotomous cutoff point of 3.352 ms presents a 
hazard ratio of 2.885 for arrhythmic SCD surrogate and a 
hazard ratio of 2.545 for total mortality. These results support 
the hypothesis that DC may predict both the SCD surrogate 
and total mortality among HF patients with depressed LVEF, 
thus emerging as a promising new tool for the arrhythmic 
risk stratification. Our multivariate Cox regression model 
was adjusted for several well-established arrhythmic predic-
tors related to different arrhythmia mechanisms (myocardial 
substrate and scar, repolarization prolongation, extrasystolic 
triggering, trend for ventricular tachyarrhythmia initiation). 
The results of the present study support the conclusion that 
DC is an important and independent risk predictor for major 
arrhythmic events among post-MI and DCM patients with 
significant systolic left ventricular dysfunction. In our study, 
the mean DC of the SCD+ surrogate group patients was 
3.2±1.8 ms and their mean LVEF was 28.0±9.2%. Our DC 
results extracted from patients with severely depressed left 
ventricular systolic function are similar to the ones reported 
in the first clinical DC study.5 It seems that the more the DC 
value decreases, the more both the risk for total mortality 
and the risk for SCD increase. In terms of physiology, it has 
been conceived that DC, by quantifying the inter-beat decel-
erations, reflects the fast parasympathetic activity regulating 
the heart rate at the sinus node level.5 Considering the phase 
rectification averaged signal technique properties,19 it has 
also been assumed that DC expresses the overall deceleration 
capacity of the sinus node without being linked necessarily to 
one particular physiological process.5 It is rational to suppose 
that DC is mainly related to the parasympathetically mediated 
autonomic regulation of the heart rate, a function character-
ized as cardioprotective.20
It is known that the parasympathetic activity is decreased 
in the HF syndrome and the degree of this impairment is 
correlated with the severity of left ventricular systolic dys-
function.21 Vagus nerve activity presents cardioprotective 
and antiarrhythmic properties20 in animal models with ex-
perimentally induced ischemia. It has been shown that vagal 
stimulation has a beneficial effect on VF thresholds22 and on 
ventricular refractoriness.23 Long lasting observations featured 
parasympathetic stimulation as a new possible therapeutic 
target in HF patients.24
In conditions where this autonomic regulation is impaired, 
alike those met in some of our post-MI and DCM patients in 
the present study, ventricular tachyarrhythmias may be facili-
tated.20 Indeed, apart from the underlying arrhythmia substrate 
of these patients with the myocardial scar, the slow conduc-
tion zones and the complex ventricular ectopy, an additional 
catecholamine mediated triggering mechanism or the absence 
of adequate cholinergically mediated protective mechanism 
may facilitate the development of malignant ventricular ar-
rhythmias related to the coexistence of autonomic dysfunction.
also performed with Cox regression, the model being adjusted 
for gender, age, diabetes, LVEF, fQRS, NSVT ≥1/24h, VPBs 
≥240/24h, QTc and DC continuous. In this model, the DC 
continuous showed a hazard ratio of 0.727 for total mortality 
(95% C.I.: 0.580 - 0.911, p value=0.006). When the cutoff point 
of DC 3.352 ms (median) was added to the same Cox regression 
model replacing the DC continuous, a hazard ratio of 2.545 
for total mortality was revealed for the patients subgroup with 
DC values below this cutoff point (95% C.I.: 1.103-5.870, p 
value =0.028 and Log rank test: p=0.011).
D I s c U s s I O N
For the first time, we investigated how the deceleration 
capacity (DC) method performs when used in arrhythmic SCD 
surrogate risk prediction by analyzing data in an HF patient 
cohort manifesting systolic ventricular dysfunction. We also 
described that the DC original method, by using a final quad 
window of averaged RR intervals, may produce negative DC 
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In our opinion, it is early to answer whether DC is a spe-
cific arrhythmic predictor or a general risk factor for all-cause 
mortality, given the lack of a prospective large study including 
a sufficient number of arrhythmic end points. To provide a 
definite answer, further studies analyzing both end points are 
required. Such studies are currently ongoing and their results 
are anticipated with interest.25-27 The physiological origin, the 
properties and the range of normal values in healthy persons 
for DC are issues for investigation.
F U t U r E  I M P L I c A t I O N s
The DC method seems complicated but as a matter of fact 
it is not; it is reliable and closely related to the physiology of 
the heart rate. The introducing researchers, proposed a fully 
automated technique limiting the inter- and intra-observer 
variability. They also employed filters to make the analysis 
even more robust. The algorithm can be clinically widely 
applied and it has already been incorporated into modern 
commercially available Holter recorders. Apart from its 
application in the risk stratification process of post-MI and 
DCM patients, it could further be used in combination with 
the heart rate turbulence method for the detection of auto-
nomic failure in several other diseases. The DC method is 
currently used in research.25-27 Hopefully, it could build up 
additional data to the autonomic nervous system assessment 
beyond the ones investigated by the conventional indices of 
the heart rate variability.
The research group that introduced the DC method es-
tablished cutoff points predicting the intermediate and high 
risk patients for total mortality.5 Whether these cutoff points 
are affected by the negative values produced by the original 
method5 and whether these cut off points can also predict 
the SCD risk or new dichotomous values need to be applied 
on different patient populations are issues requiring further 
investigation. Our research team developed two new methods, 
the DC sign of fraction that uses new filtering and the beat to 
beat DC that calculates DC from a window of two averaged 
beats.10 Both these two new DC methods were clinically applied 
and preliminary results are encouraging.28
L I M I t A t I O N s  O F  t H E  s t U D y
A major limitation of the study was its small patient sample 
size. The total sample included only 145 patients with 43 SCD 
surrogate end points. SCD is a very important issue and any 
conclusion referring to its prediction must be extracted and 
proposed with caution. Although we trust our data, we would 
welcome the results of larger prospective studies evaluating 
the DC performance for SCD prediction and duplicating 
our preliminary pilot study results. The SCD surrogate end 
point used in our study included major arrhythmia events 
occurring either clinically and spontaneously terminated or 
interrupted by an ICD. Whether these events reliably reflect 
the SCD risk has been recently questioned.29 Furthermore, 
the relatively small number of SCD end points, limits the 
multivariate analysis as the models may be adjusted only for 
a small number of variables.
c O N c L U s I O N
Decelerated capacity (DC) predicts total mortality in 
post-MI and DCM HF patients. The present study provides 
preliminary evidence that DC may also predict the arrhyth-
mic SCD risk among these patients as well. The originally 
proposed DC algorithm may in some cases produce negative 
values. Such results reflect acceleration of the heart rate rather 
than deceleration and were excluded from our analysis. The 
DC method is reliable, closely related to the physiology of 
the heart rate and the DC index is easy to be calculated via 
commercially available Holter software. In the near future, 
the method is expected to be increasingly applied in the daily 
clinical practice as it will constitute a valuable tool in the risk 
stratification process of post-MI and DCM patients.
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